ROBERTS PHARMACEUTICAL CORPORATION LAUNCHES SUPPRELIN -- ROBERTS' FIRST NEW DRUG LAUNCH IN THE U.S.
EATONTOWN, N.J., Dec. 23 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it has successfully launched SUPPRELIN(R), Roberts' first new drug launched in the United States. SUPPRELIN is an endocrine drug used to treat Central Precocious Puberty (CPP), a childhood disorder characterized by the abnormally early onset of sexual development associated with puberty. The drug will be promoted to pediatric endocrinologists who specialize in the treatment of this disease. SUPPRELIN belongs to a class of drugs known as LHRH superagonists. Roberts has another superagonist under development called SOMAGARD(R) which is in development for CPP as well as for prostate cancer and endometriosis. Roberts is developing a 60 day long-acting formulation of both compounds and expects to market this new formulation after successfully completing clinical trials and obtaining regulatory approval. "SUPPRELIN is a safe and effective drug for the treatment of Central Precocious Puberty," noted Dr. Robert A. Vukovich, Roberts' president and CEO. "We are excited by the prospect of this first launch of a new chemical entity drug by Roberts' growing sales force," he continued. Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and nonprescription products. Roberts products are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions. -0- 12/23/92 /CONTACT: Anthony P. Maris of Roberts, 908-389-1182/ (RPCX)
CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PDT
GK-LR -- NY016 -- 9523 12/23/92 11:22 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 23, 1992|
|Previous Article:||RECOGNITION ANNOUNCES MINISTRY OF TRANSPORTATION ORDER|
|Next Article:||KIRBY CORP. REPORTS RESULTS|